Pegaptanib ophthalmic Pregnancy and Breastfeeding Warnings
Brand names: Macugen
Pegaptanib ophthalmic Pregnancy Warnings
Use during pregnancy only if clearly needed.
US FDA pregnancy category: B
Comments: This drug crosses the placenta in animals.
Animal studies did not reveal evidence of teratogenicity, fetal mortality, or maternal toxicity at IV doses of up to 40 mg/kg/day (about 7000 times the recommended human dose). No information is available to evaluate the drug effect on mating or fertility. There are no controlled data in human pregnancy.
US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
Pegaptanib ophthalmic Breastfeeding Warnings
Use with caution during breastfeeding.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- Product Information. Macugen (pegaptanib ophthalmic). OSI Pharmaceuticals Inc. 2004.
References for breastfeeding information
- Product Information. Macugen (pegaptanib ophthalmic). OSI Pharmaceuticals Inc. 2004.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
